XML 76 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Revenues (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Disaggregation of Revenue [Line Items]
Revenues	$ 5,548	$ 5,281
U.S.
Disaggregation of Revenue [Line Items]
Revenues	4,006	3,818
Europe
Disaggregation of Revenue [Line Items]
Revenues	975	938
Other International
Disaggregation of Revenue [Line Items]
Revenues	567	525
Atripla
Disaggregation of Revenue [Line Items]
Revenues	95	171
Atripla | U.S.
Disaggregation of Revenue [Line Items]
Revenues	81	133
Atripla | Europe
Disaggregation of Revenue [Line Items]
Revenues	7	16
Atripla | Other International
Disaggregation of Revenue [Line Items]
Revenues	7	22
Biktarvy
Disaggregation of Revenue [Line Items]
Revenues	1,693	793
Biktarvy | U.S.
Disaggregation of Revenue [Line Items]
Revenues	1,412	739
Biktarvy | Europe
Disaggregation of Revenue [Line Items]
Revenues	181	48
Biktarvy | Other International
Disaggregation of Revenue [Line Items]
Revenues	100	6
Complera/Eviplera
Disaggregation of Revenue [Line Items]
Revenues	76	115
Complera/Eviplera | U.S.
Disaggregation of Revenue [Line Items]
Revenues	24	44
Complera/Eviplera | Europe
Disaggregation of Revenue [Line Items]
Revenues	47	62
Complera/Eviplera | Other International
Disaggregation of Revenue [Line Items]
Revenues	5	9
Descovy
Disaggregation of Revenue [Line Items]
Revenues	458	342
Descovy | U.S.
Disaggregation of Revenue [Line Items]
Revenues	363	233
Descovy | Europe
Disaggregation of Revenue [Line Items]
Revenues	61	68
Descovy | Other International
Disaggregation of Revenue [Line Items]
Revenues	34	41
Genvoya
Disaggregation of Revenue [Line Items]
Revenues	824	1,015
Genvoya | U.S.
Disaggregation of Revenue [Line Items]
Revenues	612	728
Genvoya | Europe
Disaggregation of Revenue [Line Items]
Revenues	151	193
Genvoya | Other International
Disaggregation of Revenue [Line Items]
Revenues	61	94
Odefsey
Disaggregation of Revenue [Line Items]
Revenues	409	397
Odefsey | U.S.
Disaggregation of Revenue [Line Items]
Revenues	269	282
Odefsey | Europe
Disaggregation of Revenue [Line Items]
Revenues	127	106
Odefsey | Other International
Disaggregation of Revenue [Line Items]
Revenues	13	9
Stribild
Disaggregation of Revenue [Line Items]
Revenues	53	96
Stribild | U.S.
Disaggregation of Revenue [Line Items]
Revenues	34	67
Stribild | Europe
Disaggregation of Revenue [Line Items]
Revenues	17	18
Stribild | Other International
Disaggregation of Revenue [Line Items]
Revenues	2	11
Truvada
Disaggregation of Revenue [Line Items]
Revenues	406	606
Truvada | U.S.
Disaggregation of Revenue [Line Items]
Revenues	383	551
Truvada | Europe
Disaggregation of Revenue [Line Items]
Revenues	8	33
Truvada | Other International
Disaggregation of Revenue [Line Items]
Revenues	15	22
Other HIV
Disaggregation of Revenue [Line Items]
Revenues	8	17
Other HIV | U.S.
Disaggregation of Revenue [Line Items]
Revenues	3	11
Other HIV | Europe
Disaggregation of Revenue [Line Items]
Revenues	2	1
Other HIV | Other International
Disaggregation of Revenue [Line Items]
Revenues	3	5
Revenue share - Symtuza
Disaggregation of Revenue [Line Items]
Revenues	112	66
Revenue share - Symtuza | U.S.
Disaggregation of Revenue [Line Items]
Revenues	72	42
Revenue share - Symtuza | Europe
Disaggregation of Revenue [Line Items]
Revenues	38	24
Revenue share - Symtuza | Other International
Disaggregation of Revenue [Line Items]
Revenues	2	0
AmBisome
Disaggregation of Revenue [Line Items]
Revenues	119	93
AmBisome | U.S.
Disaggregation of Revenue [Line Items]
Revenues	18	8
AmBisome | Europe
Disaggregation of Revenue [Line Items]
Revenues	59	57
AmBisome | Other International
Disaggregation of Revenue [Line Items]
Revenues	42	28
Ledipasvir/Sofosbuvir
Disaggregation of Revenue [Line Items]
Revenues	112	225
Ledipasvir/Sofosbuvir | U.S.
Disaggregation of Revenue [Line Items]
Revenues	53	117
Ledipasvir/Sofosbuvir | Europe
Disaggregation of Revenue [Line Items]
Revenues	11	27
Ledipasvir/Sofosbuvir | Other International
Disaggregation of Revenue [Line Items]
Revenues	48	81
Letairis
Disaggregation of Revenue [Line Items]
Revenues	83	197
Letairis | U.S.
Disaggregation of Revenue [Line Items]
Revenues	83	197
Letairis | Europe
Disaggregation of Revenue [Line Items]
Revenues	0	0
Letairis | Other International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Ranexa
Disaggregation of Revenue [Line Items]
Revenues	8	155
Ranexa | U.S.
Disaggregation of Revenue [Line Items]
Revenues	8	155
Ranexa | Europe
Disaggregation of Revenue [Line Items]
Revenues	0	0
Ranexa | Other International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Sofosbuvir/Velpatasvir
Disaggregation of Revenue [Line Items]
Revenues	564	491
Sofosbuvir/Velpatasvir | U.S.
Disaggregation of Revenue [Line Items]
Revenues	311	230
Sofosbuvir/Velpatasvir | Europe
Disaggregation of Revenue [Line Items]
Revenues	122	154
Sofosbuvir/Velpatasvir | Other International
Disaggregation of Revenue [Line Items]
Revenues	131	107
Vemlidy
Disaggregation of Revenue [Line Items]
Revenues	136	101
Vemlidy | U.S.
Disaggregation of Revenue [Line Items]
Revenues	73	65
Vemlidy | Europe
Disaggregation of Revenue [Line Items]
Revenues	7	4
Vemlidy | Other International
Disaggregation of Revenue [Line Items]
Revenues	56	32
Viread
Disaggregation of Revenue [Line Items]
Revenues	40	72
Viread | U.S.
Disaggregation of Revenue [Line Items]
Revenues	4	12
Viread | Europe
Disaggregation of Revenue [Line Items]
Revenues	11	14
Viread | Other International
Disaggregation of Revenue [Line Items]
Revenues	25	46
Vosevi
Disaggregation of Revenue [Line Items]
Revenues	48	63
Vosevi | U.S.
Disaggregation of Revenue [Line Items]
Revenues	33	45
Vosevi | Europe
Disaggregation of Revenue [Line Items]
Revenues	11	16
Vosevi | Other International
Disaggregation of Revenue [Line Items]
Revenues	4	2
Yescarta
Disaggregation of Revenue [Line Items]
Revenues	140	96
Yescarta | U.S.
Disaggregation of Revenue [Line Items]
Revenues	103	90
Yescarta | Europe
Disaggregation of Revenue [Line Items]
Revenues	37	6
Yescarta | Other International
Disaggregation of Revenue [Line Items]
Revenues	0	0
Zydelig
Disaggregation of Revenue [Line Items]
Revenues	20	27
Zydelig | U.S.
Disaggregation of Revenue [Line Items]
Revenues	8	11
Zydelig | Europe
Disaggregation of Revenue [Line Items]
Revenues	12	15
Zydelig | Other International
Disaggregation of Revenue [Line Items]
Revenues	0	1
Other(3)
Disaggregation of Revenue [Line Items]
Revenues	63	62
Other(3) | U.S.
Disaggregation of Revenue [Line Items]
Revenues	42	36
Other(3) | Europe
Disaggregation of Revenue [Line Items]
Revenues	18	20
Other(3) | Other International
Disaggregation of Revenue [Line Items]
Revenues	3	6
Product sales
Disaggregation of Revenue [Line Items]
Revenues	5,467	5,200
Revenues	5,467	5,200
Product sales | U.S.
Disaggregation of Revenue [Line Items]
Revenues	3,989	3,796
Product sales | Europe
Disaggregation of Revenue [Line Items]
Revenues	927	882
Product sales | Other International
Disaggregation of Revenue [Line Items]
Revenues	551	522
Royalty, contract and other revenues
Disaggregation of Revenue [Line Items]
Revenues	81	81
Royalty, contract and other revenues | U.S.
Disaggregation of Revenue [Line Items]
Revenues	17	22
Royalty, contract and other revenues | Europe
Disaggregation of Revenue [Line Items]
Revenues	48	56
Royalty, contract and other revenues | Other International
Disaggregation of Revenue [Line Items]
Revenues	$ 16	$ 3

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(1))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	srt_StatementGeographicalAxis=country_US
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_StatementGeographicalAxis=gild_OtherInternationalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsAtriplaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsBiktarvyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsCompleraEvipleraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsDescovyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsGenvoyaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsOdefseyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsStribildMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HIVProductsTruvadaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_ProductsOtherHIVMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_ProductsRevenueShareSymtuzaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsAmBisomeMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HCVProductsLedipasvirSofosbuvirMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsLetairisMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsRanexaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HCVProductsSofosbuvirVelpatasvirMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsVemlidyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsVireadMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_HCVProductsVoseviMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsYescartaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsZydeligMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_OtherProductsOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_ProductOrServiceAxis=gild_RoyaltyContractAndOtherMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: